Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Sponsor stopped the study
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Engage Health Inc. | INDUSTRY |
| Sano | OTHER |
Increase awareness of the G2019S LRRK2 mutation in Parkinson's and no cost genetic testing program.
This program is intended to increase awareness of genetic Parkinson's, in particular the G2019S LRRK2 mutation, and provide no cost genetic testing to determine if they carry the G2019S LRRK2 mutation.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| G2019S LRRK2 | Genetic | No cost genetic testing for G2019S LRRK2 |
| Measure | Description | Time Frame |
|---|---|---|
| Identify Parkinson's patients with the G2019S mutation in their LRRK2 gene | To identify Parkinson's patients with the G2019S mutation in their LRRK2 gene through whole exome sequencing in order to support the development of an oral precision medicine. | 2 years |
| Measure | Description | Time Frame |
|---|---|---|
| Understand the proportion of Parkinson's patients who have a G2019S LRRK2 mutation | To obtain information about the proportion of Parkinson's patients who have a G2019S LRRK2 mutation. | 2 years |
| Increase awareness of the importance of genetic testing in Parkinson's disease |
Not provided
Participants include those with a clinical diagnosis of Parkinson's, in particular those who have a first- or second-degree relative with Parkinson's, or who have young onset Parkinson's (age less than 50 at diagnosis) or are of Ashkenazi Jewish or North African Berber descent, or have a relative with a known genetic mutation in the LRRK2 gene, or who have a genetic mutation in the LRRK2 gene.
Inclusion Criteria:
Participant eligible for enrollment in the program must meet all of the following criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
A clinical diagnosis of Parkinson's disease
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Carrolee Barlow, MD, PhD | ESCAPE Bio | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Eurofins Genomic LLC | Louisville | Kentucky | 40299 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 33836114 | Result | Bright JM, Carlisle HJ, Toda AMA, Murphy M, Molitor TP, Wren P, Andruska KM, Liu E, Barlow C. Differential Inhibition of LRRK2 in Parkinson's Disease Patient Blood by a G2019S Selective LRRK2 Inhibitor. Mov Disord. 2021 Jun;36(6):1362-1371. doi: 10.1002/mds.28490. Epub 2021 Feb 11. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D010300 | Parkinson Disease |
| ID | Term |
|---|---|
| D020734 | Parkinsonian Disorders |
| D001480 | Basal Ganglia Diseases |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Data generation using next-generation sequencing (NGS) of human exons
To increase healthcare provider and patient awareness of the importance of genetic testing in Parkinson's disease in order to be aware of potential eligibility for clinical studies of genetic targeted medicines. |
| 2 years |
| Increase interest of healthcare providers and patients participation in clinical trials | To engage healthcare providers and patients' interest in participation in upcoming clinical studies. | 2 years |
| D009422 | Nervous System Diseases |
| D009069 | Movement Disorders |
| D000080874 | Synucleinopathies |
| D019636 | Neurodegenerative Diseases |